NCT04866134View on ClinicalTrials.gov

A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 7, 2021

Primary Completion Date

May 1, 2025

Study Completion Date

November 1, 2025

Conditions
Advanced or Metastatic Solid Tumors
Interventions
DRUG

ERAS-007

ERAS-007 will be administered orally as specified in Arm description.

DRUG

ERAS-601

ERAS-601 will be administered orally as specified in Arm description.

Trial Locations (5)

34232

Sarah Cannon Research Institute (Florida Cancer Specialists), Sarasota

37203

Sarah Cannon Research Institute (Tennessee Oncology), Nashville

75251

Mary Crowley Cancer Research, Dallas

78229

NEXT Oncology, San Antonio

80218

Sarah Cannon Research Institute (HealthONE), Denver

All Listed Sponsors
lead

Erasca, Inc.

INDUSTRY